Dynamics of glucose and insulin concentration connected to the β‐cell cycle: model development and analysis
 Martina Gallenberger^{1}Email author,
 Wolfgangzu Castell^{2},
 Burkhard A Hense^{1} and
 Christina Kuttler^{3}
DOI: 10.1186/17424682946
© Gallenberger et al.; licensee BioMed Central Ltd. 2012
Received: 25 July 2012
Accepted: 18 October 2012
Published: 19 November 2012
Abstract
Background
Diabetes mellitus is a group of metabolic diseases with increased blood glucose concentration as the main symptom. This can be caused by a relative or a total lack of insulin which is produced by the β‐cells in the pancreatic islets of Langerhans. Recent experimental results indicate the relevance of the β‐cell cycle for the development of diabetes mellitus.
Methods
This paper introduces a mathematical model that connects the dynamics of glucose and insulin concentration with the β‐cell cycle. The interplay of glucose, insulin, and β‐cell cycle is described with a system of ordinary differential equations. The model and its development will be presented as well as its mathematical analysis. The latter investigates the steady states of the model and their stability.
Results
Our model shows the connection of glucose and insulin concentrations to the β‐cell cycle. In this way the important role of glucose as regulator of the cell cycle and the capability of the β‐cell mass to adapt to metabolic demands can be presented. Simulations of the model correspond to the qualitative behavior of the glucose‐insulin regulatory system showed in biological experiments.
Conclusions
This work focusses on modeling the physiological situation of the glucose‐insulin regulatory system with a detailed consideration of the β‐cell cycle. Furthermore, the presented model allows the simulation of pathological scenarios. Modification of different parameters results in simulation of either type 1 or type 2 diabetes.
Keywords
Glucose‐insulin regulation Cell cycle Feedback loop ODE modelIntroduction
The term diabetes mellitus describes a group of metabolic diseases where cells, mainly muscle and fat cells, are not able to take up enough glucose from the blood. This can be due to a relative or absolute lack of insulin (cf.[1, 2]). Insulin is the hormone that increases the permeability of the cell membrane for glucose molecules and regulates in this way the uptake of glucose in the cells. Therefore, a lack of insulin leads to a failure of regulation of glucose homeostasis and causes the main symptom of diabetes mellitus, a persisting increased concentration of blood sugar ‐ in technical terms hyperglycemia.
The more common type 2 diabetes ‐ formerly known as adult onset diabetes ‐ is characterized by insulin resistance of the target cells. Type 1 diabetes in contrast is an autoimmune disease where the organism destroys the insulin producing β‐cells[3]. In both scenarios glucose‐insulin regulation is disturbed and the adaption of β‐cells is insufficient to compensate for this dysfunction.
 1.
Glucose is the energy source for the cells and is mainly obtained by carbohydrates in food. An elevation of blood glucose concentration is detected by the β‐cells. It causes them to release stored insulin molecules and to produce new insulin.
 2.
Insulin is the main regulator of glucose uptake in target cells. It increases the permeability of the cell membrane for glucose molecules.
 3.
The β‐cells are located in the islets of Langerhans in the pancreas. They store and produce insulin.
The following sections describe a mathematical model for the glucose‐insulin regulatory system that connects dynamics in the β‐cell with dynamics in the blood and the β‐cell cycle. The development of the model is based on the classic insulin secretion model of Grodsky[4], who used a packet distribution hypothesis also described by Ličko[5] in greater detail. In these publications insulin is assumed to be stored in packets for different release thresholds of glucose and the main objective is to account for staircase stimulations of glucose. In our work the classic model of Grodsky is extended to variable glucose and adapted to the extension with insulin and glucose blood concentrations and the β‐cell cycle. The aim of our model is not to show biochemical or biophysical processes in detail but to present the core processes and interactions in a mechanistic way. The model also provides possibilities for extensions and consideration of additional and more detailed knowledge and questions.
The paper is organized as follows. The motivation of the model, the general setup, and the development are presented in Section “Aim and development of the model”. In Section “Mathematical model” a detailed description of the mathematical model is shown. The mathematical analysis is presented in Section “Analysis of the model” and simulations of the model in Section “Simulation”. The results are summarized and discussed in Section “Discussion”.
Aim and development of the model
Several publications[6]‐[8] discuss the relevance of the β‐cell mass for the development of diabetes mellitus. Normally there is a slow turnover of β‐cells (see[9]) but the β‐cell mass can adapt to metabolic demands[7, 8]. The concept of dynamic β‐cell mass was under discussion for some time but is now generally accepted. Nevertheless, there is a controversy on the mechanisms and the precise growth factors responsible for this adaption[6, 9, 10]. It was shown that elevated glucose levels enhance β‐cell replication[11, 12]. More precisely, Porat et al.[13] identify the glucose metabolism via glucokinase as the main positive regulator of β‐cell proliferation. As the model in our work does not explicitly account for the glucose metabolism, the more general approach of glucose concentration as regulator of β‐cell proliferation is used.
Mathematical models to understand the processes of the glucose‐insulin regulatory system have a long history. Starting with the pioneering work of Bolie[14] in the 1960s one of the first widely used models was the minimal model developed by Bergman and coworkers (see[15, 16]) in the beginning of the 1980s. Elaborate reviews of different models using ODE, PDE, DDE, and integro‐differential equations (IDE) are given for example in Makroglou et al.[17] or Boutayeb and Chetouani[18]. In the last decade, several models dealing with the interplay of glucose, insulin, and β‐cell mass have been developed. For example see the work of de Winter et al.[19], Topp et al.[20], De Gaetano et al.[21], or the delay‐model of Li et al.[22]. Other models consider particular aspects, as, e.g., electrical activity of β‐cells in Cha et al.[23], islet size distribution in Jo et al.[24], or glucose regulation in the whole‐body system in Kang et al.[25]. Other models are designed to control the maintenance of normoglycemia in patients, like the compartment model in[26].
In our approach, based on the results in[6]‐[11], instead of modeling β‐cell mass the whole β‐cell cycle is taken into account and plays an important role in the regulatory system. The main aspect of our model is the coupling of insulin storage and of insulin and glucose blood concentrations with the β‐cell cycle. It provides the possibility to study precisely the mechanism of glucose influence on the β‐cell cycle and therefore on β‐cell mass. The model shows the dynamics of glucose and insulin with influence of glucose on the β‐cell cycle. Therefore, the dynamics in the blood are directly connected with the mechanisms in the islets of Langerhans.
 1.
The fastest feedback loop consists in a release of stored insulin immediately after glucose stimulus via elevated blood glucose concentrations [4]. This first insulin peak reaches its maximum after about three to five minutes.
 2.
The second feedback loop is due to the glucose dependent enhancement of insulin provision. This has a visible effect after about 10 minutes [4].
 3.
The slowest feedback loop consists of the enhancement of the β‐cell cycle by glucose. If the first two reactions of the system are not sufficient to end hyperglycemia, the blood glucose concentration remains at an elevated level. This mild hyperglycemia results in an enhancement of the β‐cell cycle leading to more β‐cells which in turn can produce further insulin (see [9]).
There are different processes that increase β‐cell mass via cell number[8, 9]. Besides replication of existing cells, there is also neogenesis by transdifferentiation and stem cells. As an assumption in our paper, based on publications[27]‐[29], the adaption of β‐cell mass is managed by replication only.
Besides the uptake of glucose through food, there is also a production of glucose by the organism itself incorporated into the model with a constant production rate. The glucose stimulus induces the organism to release stored insulin and to enhance insulin provision. Insulin is stored in packets for different release thresholds[4]. The storage is filled through glucose dependent insulin provision and cleared at a constant secretion rate. Secreted insulin regulates the uptake of glucose in muscle and fat cells. Besides the immediate release and enhanced provision per cell, the model also accounts for the slowest regulation feedback loop, i.e. glucose influencing the β‐cell cycle. The replication of β‐cells eventually leads to the provision of more insulin.
The aim of our work is to describe the three different feedback loops in one model and to provide a basis for understanding and explanation of the mechanisms in the glucose‐insulin regulatory system.
The different parts of the model will be described in detail in the following section.
Mathematical model
β‐cell cycle
The mathematical model consists of three parts where the first one is the β‐cell cycle.
 1.
The G _{1}‐phase is a growth phase where the cell prepares for synthesis. A basic assumption of the model is that the functioning β‐cell mass lies in this phase [31].
 2.
The S‐phase is the synthesis phase where DNA replicates.
 3.
The G _{2}/M‐phase is the premitosis and mitosis phase where the nuclear division takes place.
Biological experiments concerning the cell cycle are often done by flow cytometry. This method measures the DNA content in the different phases and can not distinguish between phases G_{2} and M that have the same DNA content. Therefore, both are combined to one G_{2}/M‐phase.
Model parameters
Value  Definition  

p _{1}  $6.0594\times 1{0}^{5}\frac{1}{min}$  transition rate G_{1} → S 
p _{2}  $4.9861\times 1{0}^{3}\frac{1}{min}$  transition rate S → G_{2}/M 
p _{3}  $8.9444\times 1{0}^{4}\frac{1}{min}$  transition rate G_{2}/M → G_{1} 
p _{4}  $3.3194\times 1{0}^{4}\frac{1}{min}$  apoptosis rate 
p _{5}  $0.056\frac{100\phantom{\rule{0.3em}{0ex}}\text{ml}}{\text{mg}}$  influence factor of glucose 
p _{6}  0.3$\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}\phantom{\rule{1em}{0ex}}min}$  rate of glucose production 
p _{7}  0.003$\frac{1}{min}$  glucose effectiveness 
at zero insulin  
p _{8}  $360\times 1{0}^{3}\frac{100\phantom{\rule{0.3em}{0ex}}\text{ml}}{\text{mg min}}$  insulin sensitivity 
p _{9}  0.622$\frac{1}{min}$  secretion rate of insulin 
p _{10}  0.3$\frac{1}{min}$  decay rate of insulin 
p _{11}  0.0337$\frac{1}{min}$  rate of provision increase 
p _{12}  1.72×10^{−9} mg  average insulin amount per β‐cell 
bv  3.33 ml  blood volume of 35g mouse 
f  0.5  proportionality factor 
h  5  Hill coefficient 
P _{0}  186.506$\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$  Michaelis constant 
${\stackrel{\u0304}{X}}_{\mathit{\text{max}}}$  1.65×10^{−3} mg  maximal amount of insulin 
per pancreas  
k  3.3  Hill coefficient 
C  149.78$\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$  Michaelis constant 
An important contributing factor to the β‐cell dynamics is glucose toxicity described by Unger et al.[33]. This term refers to the wide range of harmful effects of chronic hyperglycemia leading to chronic oxidative stress after the onset of diabetes, including damages to the pancreatic islet β‐cell (cf.[34, 35]). As a consequence of hyperglycemia lipid toxicity may additionally damage β‐cells. This effect is called glucolipotoxicity and is described in[36]. To account for the effects of glucose toxicity and glucolipotoxicity on insulin secretion a glucose dependent apoptosis rate can be incorporated to the cell cycle. In the actual version of the model the role of glucose toxicity is omitted for the sake of simplicity and the apoptosis rate is constant. As an assumption in the β‐cell cycle model, apoptosis and the only under some pathological conditions relevant necrosis are subsumed in the rate p_{4} called apoptosis rate[37].
The constant 2 in the first equation accounts for cell division in the transition from G_{2}/M‐ to G_{1}‐phase. In the physiological case for adults the β‐cell cycle is very slow (see[9]) but has the capability of dynamic adaption to metabolic demands[7]. In model (1) glucose influences the transition rate p_{1} from G_{1}‐ to S‐phase and is able to regulate the β‐cell cycle. This is the case if glucose triggers the system and neither the immediate release of stored insulin nor the enhanced insulin provision is able to lower blood glucose concentration. Then a high level of glucose forces the cell cycle to accelerate.
Glucose and insulin concentration in the blood
The net rate of glucose production is represented by a constant production rate p_{6}. This rate is the difference of an intrinsic glucose production, mainly by the liver, and glucose concentration independent uptake of glucose. The latter consists mainly of glucose uptake by the brain and other nervous tissues which is assumed to be constant in our model. The uptake of glucose in other tissues consists of two processes dependent on the glucose blood concentration. One is an insulin independent uptake represented by the parameter of glucose effectiveness p_{7}. The other process is an insulin dependent glucose uptake mainly by muscle and fat cells which is influenced by insulin sensitivity p_{8} and depends on blood insulin concentration I. The parameters are listed in Table1.
where secretion consists of the secreted amount of insulin molecules from the β‐cells, p_{9}X_{1}, that has to be considered with respect to the blood volume bv of the organism. Variable X_{1} will be discussed in detail in the following section. Degradation of insulin is modeled with a constant decay rate p_{10}.
Insulin storage
In 1972, Grodsky published a packet distribution hypothesis for insulin granules in an insulin storage[4]. In this work the storage is modeled with no dynamic connection to the remaining glucose‐insulin regulatory system. For stimulation of the system, different glucose functions were considered, for example single‐ or two‐step constant stimulation, staircase stimulation, or ramp functions of glucose concentration.
In our approach the model of Grodsky is incorporated into a model of the glucose‐insulin regulatory system including the adaption of β‐cell mass to metabolic demands. Although the publication of this insulin secretion model is several years ago, the packet distribution hypothesis still finds application, for example in the work of Overgaard et al.[39]. There, it is included into a mathematical model for insulin secretion applied to IVGTT and OGTT data. Also Pedersen et al. presented an updated version of the hypothesis for oral minimal models of insulin secretion in[40] and Tsaneva‐Atanasova described insulin secretion in a general context of mechanisms of cell secretion[41].
As the knowledge about β‐cell biology has increased since 1972 some reinterpretation of the assumptions in[4] are appropriate. In the original work there is no clear definition of what the packets are. They could be interpreted as insulin containing granules within a cell with different sensitivities for glucose induced release. Although granules clearly are present and variability of sensors for signals is a common feature in biology, there is no direct experimental proof, yet, to our knowledge. An alternative interpretation would be variability of sensitivity on cell level. In fact, Jonkers and Henquin[42] show a sigmoidal distribution of active β‐cells. A combination of both aspects (and possibly more unknown factors) may be the most probable explanation for the experimentally found dose‐response curves[43]. Therefore, in the following the packets are interpreted as pancreatic β‐cells that can be active or inactive. Several recent models for insulin secretion considering Ca^{2 +} ‐evoked exocytosis, the cAMP amplifying pathway, and actual results on granule dynamics are available (see e.g.[44]‐[46]) but for the qualitative conclusions in our work Grodsky’s basic model of insulin secretion is sufficient.
The initial packet distribution ξ(θ,0) for threshold θ at time t=0 is crucial for the storage model. In every time step the different processes within the storage try to achieve this initial distribution at least qualitatively.
The storage is filled through a glucose dependent insulin provision factor P, and insulin is released with constant secretion rate p_{9}. Besides that, there is a redistribution process where packets that were not needed so far are redistributed to qualitatively reestablish the initial packet distribution ξ(θ,0).
These packets can not be released for glucose concentration G but are involved in the redistribution process.
As, in our work, the insulin storage is connected to the β‐cell cycle, changes in the insulin producing β‐cell mass influence also the initial distribution ξ(θ,0) as it is dependent on the maximum amount of insulin per pancreas,${\stackrel{\u0304}{X}}_{\mathit{\text{max}}}$. The insulin producing β‐cell mass can change in every time step t and thus${\stackrel{\u0304}{X}}_{\mathit{\text{max}}}$ is time dependent, too. Therefore, this distribution is called target distribution and is denoted by ξ^{∗}(θ,t). Consequences of this modification are shown later in this section.
System (4) shows the production and redistribution process in detail according to the target distribution ξ^{∗}(θ,t). Their contribution to the dynamics of the single compartments are modeled with proportionality factors f and$\stackrel{~}{f}$, respectively.
The parameters of the model are given in Table1. The glucose dependent transition functions u_{1},…,u_{4} describe provision and redistribution processes according to the target distribution. They are given in greater detail in Appendix “Transition functions” section.
with h being the Hill coefficient and P_{0} the Michaelis constant.
where ξ^{∗}(θ,t) is now called target distribution.
Complete model
 1.
Insulin I influences the glucose dynamics via insulin dependent uptake in target cells. Secretion of insulin consists of the releasable amount of insulin molecules p _{9} X _{1} in relation to the blood volume bv.
 2.
Glucose G plays an important role in regulating the processes within the insulin secretion model. It regulates the provision of insulin and defines the compartments of the insulin storage via the target distribution. It also contributes to the redistribution process. Furthermore, glucose regulates the β‐cell cycle via the glucose dependent transition rate from G _{1}‐ to S‐phase.
 3.
The β‐cell mass G _{1} determines the capacity of insulin provision.
In Section “Simulation” the behavior of solutions of the complete model can be seen. There, the model is simulated in the physiological case as well as in an experimental situation.
Analysis of the model
In this section a basic mathematical analysis is presented to achieve a better understanding of the model behavior. First, positivity of the solution is shown. Then the analysis focusses on steady states and their stability to explain the asymptotic development of the solution.
Positivity of solutions
Our model of the glucose‐insulin regulatory system describes the dynamics of biological quantities, e.g., cell numbers, concentrations, and mass. Naturally, these quantities are positive and therefore positivity of the solution is a desired characteristic of the system. A necessary and sufficient condition for the existence of positive solutions is given in the following corollary.
Corollary 1
i = 1,…,m, for all t > 0 and$x\in {\mathbb{R}}_{+}^{m}$.
Initial values
Variable  Initial Value  Definition 

G_{1}(0)  958000  number of cells in G_{1}‐phase 
S(0)  14000  number of cells in S‐phase 
G_{2}/M(0)  28000  number of cells in G_{2}/M‐phase 
G(0)  200$\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$  blood glucose concentration 
I(0)  0.01$\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$  blood insulin concentration 
X_{1}(0)  0.0012 mg  releasable amount of insulin 
X_{2}(0)  0.0005 mg  non‐releasable amount of insulin 
P(0)  0  provision of insulin 
Steady states
As it can be seen in Section ‘Simulation’, the graph of the solution suggests a steady state behavior of the system. The investigation of the steady states is based on the β‐cell cycle model (1).
Equation (12) results in a fixed value for glucose,$\hat{\text{G}}$, that can be modified via the influence factor p_{5}.$\hat{\text{G}}$ is a crucial threshold for the development of the cell cycle as it determines the values of glucose concentration leading to β‐cell mass increase or decrease.
In this case there are more β‐cells dying than dividing per time step and in consequence the total amount of β‐cells in G_{1}‐phase is decreasing.
Fewer β‐cells are dying than dividing per time step and in consequence the β‐cell mass in G_{1}‐phase is increasing.
with all cell numbers in the three phases equal to zero. As it can be seen in${F}_{1}^{\ast}$, glucose concentration is never equal to zero due to constant production of glucose by the liver. Thus, the steady state of the provision factor, P_{ ∞ }, is also not equal to zero but a fixed value depending on${G}^{\ast}=\frac{{p}_{6}}{{p}_{7}}$.
The steady state${F}_{2}^{\ast}$ is reached after a glucose stimulus to the regulatory system. The variables tend to these values if no further impulse or modification to the system is following.
Stability
The stability of the two steady states${F}_{1}^{\ast}$ and${F}_{2}^{\ast}$ can be investigated by computing the Jacobian matrix of these fixed points. This analysis is based on the system parameters in Table1.
 1.The trivial steady state with cell numbers equal to zero,${F}_{1}^{\ast}=\left(0,0,0,\frac{{p}_{6}}{{p}_{7}},0,0,0,{P}_{\infty}\left(\frac{{p}_{6}}{{p}_{7}}\right)\right),$
 2.The non‐trivial steady state,${F}_{2}^{\ast}=\left({G}_{1}^{\ast},{S}^{\ast},{G}_{2}/{M}^{\ast},{G}^{\ast},{I}^{\ast},{X}_{1}^{\ast},{X}_{2}^{\ast},{P}^{\ast}\right),$
is a stable fixed point reached by the system after some time without any influence from the outside.
The behavior of the model according to the mathematical analysis will be illustrated in the following section using simulations of the complete model.
Simulation
In this section two simulations of the complete model (9) are presented. The first simulation describes the behavior of the glucose‐insulin regulatory system in the physiological case. The second simulation particularly shows the adaption of β‐cell mass under long term glucose infusion[12].
The physiological case ‐ given in Figure5 ‐ has been simulated over 120 minutes with a high initial glucose value resulting for example from recent food intake. Parameters and initial values of the variables are given in Tables1 and2, respectively. The following description discusses the subplots.

Figure5a: With the given parameters the threshold value for the cell cycle is$\hat{\text{G}}=80\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$. Glucose concentration G is above this level for 120 minutes. Therefore, the cell cycle reacts in the following way: Glucose values above the threshold increase the transition rate from G_{1}‐ to S‐phase. As the β‐cell cycle is a slow process, in the first 120 minutes an only slight increase in S‐ and G_{2}/M‐phase is detectable while the cell number in G_{1}‐phase is decreasing. Increase in β‐cell mass, i.e., G_{1}, takes more than 120 minutes. As glucose concentration is almost at the steady state$\hat{\text{G}}=80\frac{\text{mg}}{100\phantom{\rule{0.3em}{0ex}}\text{ml}}$ towards the end of the simulation, the system will regulate itself without significant adaption of β‐cell mass. This is expected in the physiological case without abnormal exposure to glucose.

Figure5b: The releasable amount of insulin X_{1} shows a biphasic behavior. There is a first peak release of stored insulin molecules and a second phase in consequence of provision of further insulin.

Figure5c: With decreasing glucose concentration there are more packets with threshold value above the actual glucose level. For this reason and due to enhanced insulin provision P the amount of non‐releasable insulin X_{2} increases.

Figure5d: Glucose concentration G is decreasing from the high initial value as there is an increased concentration of insulin I in the blood.

Figure5e: Blood insulin concentration I follows with some delay the releasable amount of insulin. It also shows the characteristic biphasic behavior of insulin release.

Figure5f: Provision factor P shows an increase in presence of high glucose values and decreases as blood glucose decreases.
Discussion
 1.
Immediate release of stored insulin molecules.
 2.
Enhancement of provision of new insulin.
 3.
Adaption of the β‐cell cycle to metabolic demands.
This is possible by incorporating an insulin secretion model describing storage and release of insulin molecules on the one hand and insulin provision on the other hand[4]. Furthermore, insulin provision is glucose dependent which allows its adaption to specific demands of the organism at every time step. The third feedback loop is modeled via incorporation of the β‐cell cycle with glucose regulating the replication rate of the cells[11, 13].
Several models of the glucose‐insulin regulatory system, as e.g.,[19]‐[21], describe glucose, insulin and β‐cell mass dynamics, whereas our model shows the connection of glucose, and insulin concentrations with the β‐cell cycle as the main aspect. In this way the important role of glucose as regulator of the cell cycle[13] and the capability of the β‐cell mass to adapt to metabolic demands can be analyzed in detail. Hereby, the adaption of β‐cell mass is assigned exclusively to hyperplasia and disregards hypertrophy.
The model conserves typical characteristics of the glucose‐insulin regulatory system. The plots of the complete model in Figure5 show biphasic insulin release represented through the biphasic shape of the releasable amount of insulin X_{1}. This is a typical behavior of insulin release reported in several biological publications (e.g.[47, 50]).
Modeling insulin secretion based on[4] incorporates three feedback loops consisting of stored insulin, provision of further insulin, and variable β‐cell mass. Our model expands classic insulin secretion models (e.g.[4, 44]‐[46]) by a connection to the β‐cell cycle.
The qualitative behavior of the model is illustrated with simulations. In the physiological case, shown in Figure5, the β‐cell mass is sufficient to produce and release enough insulin to decrease glucose concentration and maintain euglycemia. With a second simulation the adaption of the β‐cell mass to increasing metabolic demands is presented. This situation occurs in long term studies with persisting hyperglycemia as it can be seen in Figure6. In a simulation similar to the experiment in[12] increase of β‐cell mass via hyperplasia in 96 hours of hyperglycemia is shown.
The analysis of the model gives the existence of two steady states. One describes a trivial fixed point with β‐cell numbers in all three phases equal to zero. The second steady state is a stable fixed point resulting from successfully achieving euglycemia. The trivial steady state is unstable while the stable non‐trivial steady state will be attained in both situations shown in Figures5 and6 with longer simulation times. The stability of the steady states is dependent on the underlying parameter values. As the parameters in our model are chosen in a way to describe a physiological situation the trivial steady state is unstable and will not be reached. However, there are scenarios where the β‐cells in the model eventually die out. This could be due to an abnormally high apoptosis rate p_{4} or artificially holding of the glucose concentration below the threshold value$\u011c$ by external insulin infusion, for example. While a reduction of the replication rate due to hypoglycemia is shown in[11] a complete disappearance of the β‐cell mass is an implausible result. The death of the organism would happen prior to the extinction of the β‐cells.
Our system allows for simulation of the glucose‐insulin regulatory system assuming in vivo situations. Our model builds a theoretical basis for description and explanation of dynamics derived from biological experiments. It supports the understanding of metabolic processes. Biological assumptions can be verified and quantification of data and parameters can be achieved. Additionally, the model promotes understanding of the interplay of the three different regulation feedback loops. The model is able to describe metabolic dynamics of the glucose‐insulin regulatory system also for the pathological case of type 1 or type 2 diabetes.
To illustrate one possible modification of the system a type 2 diabetes‐like simulation is done. Type 2 diabetes is characterized by insulin resistance of target cells, mainly muscle and fat cells. In consequence, these cells are not able to take up enough glucose from the blood. In this case the insulin sensitivity of the body cells is down‐regulated. To simulate this situation the model parameter for insulin sensitivity p_{8} is decreased arbitrary from the value p_{8} = 360 × 10^{−3}to${\stackrel{~}{p}}_{8}=360\times 1{0}^{5}$ while the other parameters given in Table1 stay the same. This modification corresponds to a lower reaction of the target cells to insulin and therefore a decreased uptake of glucose from the blood.
There are also possibilities to simulate the regulatory system in a type 1 diabetes scenario. It can be done for example by increasing the apoptosis rate p_{4} in the cell cycle model. This results in dying β‐cells which is characteristic for this autoimmune disease. For a more detailed discussion about β‐cell mass in a type 1 diabetes scenario see Klinke[51]. There, β‐cell mass at onset of type 1 diabetes is concerned depending on body weight and the patient’s age.
In summary, our model is a basic approach to understand the processes within the glucose‐insulin regulatory system connected to the β‐cell cycle. It offers a wide range of possible modifications to incorporate further processes and can be adapted to many biological questions.
Appendix
Derivation of glucose dependent insulin storage dynamics
To determine these integrals, the differential equation for ξ(θ t), given in[4], ‐ has to be solved first. Then this solution can be applied to the expressions for X_{1} and X_{2}. In a final step we differentiate these terms with respect to time t to achieve differential equations$\stackrel{\u0307}{{X}_{1}}$ and$\stackrel{\u0307}{{X}_{2}}$.
Solution of the differential equation$\stackrel{\u0307}{\xi}(\theta ,t)$
The only difference between the two equations is the term for insulin secretion, −p_{9}ξ(θ,t), that occurs in the first but not in the second equation. Therefore, we restrict the following exploration to the case θ ≤ G(t).
The constant C incorporates the initial conditions by C = ξ_{0}(θ).
Derivation of the differential equations$\stackrel{\u0307}{{X}_{1}}\left(t\right)$ and$\stackrel{\u0307}{{X}_{2}}\left(t\right)$
with target distribution ξ^{∗}(θ,t).
with target distribution ξ^{∗}(θ,t).
Transition functions
This expression was found by analyzing condition (19) in steady state situation.
These expressions were used for the simulations in Figures5 and6.
Declarations
Acknowledgements
The authors thank Marcus Ansorg for many fruitful discussions and his help during the modeling process.
Authors’ Affiliations
References
 Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001, 414: 799806. 10.1038/414799a.View ArticlePubMed
 Khan AH, Pessin JE: Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002, 45: 14751483. 10.1007/s0012500209747.View ArticlePubMed
 Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res. 1985, 4: 110125.PubMed
 Grodsky GM: A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest. 1972, 51: 20472059. 10.1172/JCI107011.PubMed CentralView ArticlePubMed
 Ličko V: Threshold secretory mechanism: a model of derivative element in biological control. Bull Math Biol. 1973, 35: 5158.View ArticlePubMed
 Sachdeva MM, Stoffers DA: Minireview: meeting the demand for insulin: molecular mechanisms of adaptive postnatal β‐cell mass expansion. Mol Endocrinol. 2009, 23: 747758. 10.1210/me.20080400.PubMed CentralView ArticlePubMed
 Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA: Very slow turnover of β‐cells in adult mice. Diabetes. 2005, 54: 25572567. 10.2337/diabetes.54.9.2557.View ArticlePubMed
 Bonner‐Weir S, Li WC, Ouziel‐Yahalom L, Guo L, Weir GC, Sharma A: β‐cell growth and regeneration: replication is only part of the story. Diabetes. 2010, 59: 23402348. 10.2337/db100084.PubMed CentralView ArticlePubMed
 Bouwens L, Rooman I: Regulation of pancreatic beta‐cell mass. Physiol Rev. 2005, 85: 12551270. 10.1152/physrev.00025.2004.View ArticlePubMed
 Heit JJ, Karnik SK, Kim SK: Intrinsic regulators of pancreatic β‐cell proliferation. Annu Rev Cell Dev Biol. 2006, 22: 311338. 10.1146/annurev.cellbio.22.010305.104425.View ArticlePubMed
 Pechhold K, Koczwara K, Zhu X, Harrison VS, Walker G, Lee J, Harlan DM: Blood glucose levels regulate pancreatic β‐cell proliferation during experimentally‐induced and spontaneous autoimmune diabetes in mice. PloS ONE. 2009, 4: e482710.1371/journal.pone.0004827.PubMed CentralView ArticlePubMed
 Bonner‐Weir S, Deery D, Leahy JL, Weir GC: Compensatory growth of pancreatic β‐cells in adult rats after short‐term glucose infusion. Diabetes. 1989, 38: 4953. 10.2337/diabetes.38.1.49.View ArticlePubMed
 Porat S, Weinberg‐Corem N, Tornovsky‐Babaey S, Schyr‐Ben‐Haroush R, Hijy A, Stolovich‐Rain M, Dadon D, Granot Z, Ben‐Hur V, White P, Girard CA, Karni R, Kaestner KH, Ashcroft FM, Magnuson MA, Saada A, Grimsby J, Glaser B, Dor Y: Control of pancreatic β‐cell regeneration by glucose metabolism. Cell Metab. 2011, 13: 440449. 10.1016/j.cmet.2011.02.012.View ArticlePubMed
 Bolie VW: Coefficients of normal blood glucose regulation. J Appl Physiol. 1961, 16: 783788.PubMed
 Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol. 1979, 23: E667E677.
 Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C: Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes. 1980, 29: 979990. 10.2337/diabetes.29.12.979.View ArticlePubMed
 Makroglou A, Li J, Kuang Y: Mathematical models and software tools for the glucose‐insulin regulatory system and diabetes: an overview. Appl Numer Math. 2006, 56: 559573. 10.1016/j.apnum.2005.04.023.View Article
 Boutayeb A, Chetouani A: A critical review of mathematical models and data used in diabetology. Biomed Eng Online. 2006, 5: 4310.1186/1475925X543.PubMed CentralView ArticlePubMed
 de Winter, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M: A mechanism‐based disease progression model for comparison of long‐term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn. 2006, 33: 313343. 10.1007/s1092800690082.View Article
 Topp B, Promislow K, De Vries G, Miura RM, Finegood DT: A model of β‐cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol. 2000, 206 (4): 605619. 10.1006/jtbi.2000.2150.View ArticlePubMed
 De Gaetano A, Hardy T, Beck B, Abu‐Raddad E, Palumbo P, Bue‐Valleskey J, Pørksen N: Mathematical models of diabetes progression. Am J Physiol Endocrinol Metab. 2008, 295: E1462E1479. 10.1152/ajpendo.90444.2008.View ArticlePubMed
 Li J, Kuang Y, Mason CC: Modeling the glucose‐insulin regulatory system and ultradian insulin secretory oscillations with two explicit time delays. J Theor Biol. 2006, 242: 722735. 10.1016/j.jtbi.2006.04.002.View ArticlePubMed
 Cha CY, Powell T, Noma A: Analyzing electrical activities of pancreatic β cells using mathematical models. Prog Biophys Mol Biol. 2011, 107: 265273. 10.1016/j.pbiomolbio.2011.08.001.View ArticlePubMed
 Jo J, Hara M, Ahlgren U, Sorenson R, Periwal V: Mathematical models of pancreatic islet size distributions. Islets. 2012, 4: 1019. 10.4161/isl.18660.PubMed CentralView ArticlePubMed
 Kang H, Han K, Choi M: Mathematical model for glucose regulation in the whole‐body system. Islets. 2012, 4: 8493. 10.4161/isl.19505.View ArticlePubMed
 Schaller HC, Schaupp L, Bodenlenz M, Wilinska ME, Chassin LJ, Wach P, Vering T, Hovorka R, Pieber TR: On‐line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with type 1 diabetes. Diabetic Med. 2006, 23: 9093. 10.1111/j.14645491.2006.01695.x.View ArticlePubMed
 Dor Y, Brown J, Martinez OI, Melton DA: Adult pancreatic β‐cells are formed by self‐duplication rather than stem‐cell differentiation. Nature. 2004, 429: 4146. 10.1038/nature02520.View ArticlePubMed
 Georgia S, Bhushan A: β cell replication is the primary mechanism for maintaining postnatal β‐cell mass. J Clin Invest. 2004, 114: 963968.PubMed CentralView ArticlePubMed
 Teta M, Rankin MM, Long SY, Stein GM, Kushner JA: Growth and regeneration of adult β cells does not involve specialized progenitors. Dev Cell. 2007, 12: 817826. 10.1016/j.devcel.2007.04.011.View ArticlePubMed
 Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Molecular Biology of the Cell. Garland Science. 2008, New York, Abingdon: Taylor & Francis
 Meng ZX, Nie J, Ling JJ, Sun JX, Zhu YX, Gao L, Lv JH, Zhu DY, Sun YJ, Han X: Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia. 2009, 52: 125135. 10.1007/s001250081174x.View ArticlePubMed
 Cozar‐Castellano I, Harb G, Selk K, Takane K, Vasavada R, Sicari B, Law B, Zhang P, Scott DK, Fiaschi‐Taesch N, Stewart AF: Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines. Diabetes. 2008, 57: 30563068. 10.2337/db080393.PubMed CentralView ArticlePubMed
 Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985, 28: 119121.View ArticlePubMed
 Yki‐Järvinen H: Glucose toxicity. Endocr Rev. 1992, 13: 415431.PubMed
 Robertson RP, Harmon JS: Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med. 2006, 41: 177184. 10.1016/j.freeradbiomed.2005.04.030.View ArticlePubMed
 Poitout V, Robertson RP: Glucolipotoxicity: fuel excess and β‐cell dysfunction. Endocr Rev. 2008, 29: 351366.PubMed CentralView ArticlePubMed
 Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic β‐cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005, 54: S97S107. 10.2337/diabetes.54.suppl_2.S97.View ArticlePubMed
 Daukste L, Basse B, Baguley BC, Wall DJN: Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. J Theor Biol. 2009, 260 (4): 563571. 10.1016/j.jtbi.2009.06.019.View ArticlePubMed
 Overgaard RV, Jelic K, Karlsson M, Henriksen JE, Madsen H: Mathematical beta cell model for insulin secretion following IVGTT and OGTT. Ann Biomed Eng. 2006, 34: 13431354. 10.1007/s1043900691540.View ArticlePubMed
 Pedersen MG, Toffolo GM, Cobelli C: Cellular modeling: insight into oral minimal models of insulin secretion. Am J Physiol Endocrinol Metab. 2010, 298: E597E601. 10.1152/ajpendo.00670.2009.View ArticlePubMed
 Tsaneva‐Atanasova K, Osinga HM, Tabak J, Pedersen MG: Modeling mechanisms of cell secetion. Acta Biotheor. 2010, 58: 315327. 10.1007/s1044101091158.View ArticlePubMed
 Jonkers FC, Henquin JC: Measurements of cytoplasmic Ca2+ in islet cell clusters show that glucose rapidly recruits β‐cells and gradually increases the individual cell response. Diabetes. 2001, 50: 540550. 10.2337/diabetes.50.3.540.View ArticlePubMed
 Henquin JC: Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia. 2009, 52: 739751. 10.1007/s001250091314y.View ArticlePubMed
 Fridlyand LE, Philipson LH: Coupling of metabolic, second messenger pathways and insulin granule dynamics in pancreatic beta‐cells: A computational analysis. Prog Biophys Mol Biol. 2011, 107: 293303. 10.1016/j.pbiomolbio.2011.09.001.PubMed CentralView ArticlePubMed
 Pedersen MG, Corradin A, Toffolo GM, Cobelli C: A subcellular model of glucose‐stimulated pancreatic insulin secretion. Phil Trans R Soc A. 2008, 366: 35252543. 10.1098/rsta.2008.0120.View ArticlePubMed
 Bertuzzi A, Salinari S, Mingrone G: Insulin granule trafficking in beta‐cells: mathematical model of glucose‐induced insulin secretion. Am J Physiol Endocrinol Metab. 2007, 293: E396E409. 10.1152/ajpendo.00647.2006.View ArticlePubMed
 Curry DL, Bennett LL, Grodsky GM: Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology. 1968, 83: 572584. 10.1210/endo833572.View ArticlePubMed
 Grodsky GM, Curry D, Landahl H, Bennett L: Furtherstudies on the dynamic aspects of insulin release in vitro with evidence for a two‐compartmental storage system. Acta Diabetol Lat. 1969, 6: 554579.PubMed
 Pavel NH: Differential Equations, Flow Invariance and Applications. 1984, Boston: Pitman Pub
 Nesher R, Cerasi E: Modeling phasic insulin release ‐ immediate and time‐dependent effects of glucose. Diabetes. 2002, 51: 5359. 10.2337/diabetes.51.2007.S53.View Article
 Klinke DJ: Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS ONE. 2008, 3: e137410.1371/journal.pone.0001374.PubMed CentralView ArticlePubMed
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.